AgingResearch.NewsJoin free

SAFIT2

SAFIT2 has been studied in 2 papers since 2023: 1 observational study in people, 1 in cells. The newest paper, Apr 1, 2025: “FKBP5 Induces Senescence in BMSCs and Inhibits Osteogenic Differentiation Through the Canonical WNT/β-Catenin Signalling Pathway in Senile Osteoporosis”.

Intervention

2 papers study it2 findingsUpdated

PubChem

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 1 country
  • Funders: China Postdoctoral Science Foundation and 4 more
  • Humans1
  • Cells1

What did studies of SAFIT2 find?

2

Studies of SAFIT2 measured 2 outcomes; the most studied are bone mineral density (1 study) and bone density (1).

Bone mineral density

upin animals1

1 study

  1. SAFIT2 improves bone mineral density.

    “administration of SAFit2, a selective FKBP5 inhibitor, enhanced bone mineral density in an animal model of senile osteoporosis.”

    Animalsin an animal model of senile osteoporosis

    FKBP5 Induces Senescence in BMSCs and Inhibits Osteogenic Differentiation Through the Canonical WNT/β-Catenin Signalling Pathway in Senile Osteoporosis

    Journal of cellular and molecular medicine

More on Bone mineral density

Bone density

upin animals1

1 study

  1. SAFIT2 improves bone density.

    “Administration of SAFit2, a selective inhibitor of FKBP5, enhanced bone density in an animal model of senile osteoporosis.”

    Animalsin an animal model of senile osteoporosisbone

    FKBP5 drives bone marrow stem cells senescence and suppresses osteogenic differentiation via canonical WNT/β-catenin signaling pathway

    Research SquarePreprint

Latest

Related